GT
ANIP icon

Glenmede Trust’s ANI Pharmaceuticals ANIP Stock Holding History

Glenmede Trust’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-54
Closed -$1K – 1251
2020
Q3 		$1K Sell
54
-12
-18% -$357 ﹤0.01% 2318
2020
Q2 		$2K Sell
66
-29
-31% -$1.04K ﹤0.01% 2213
2020
Q1 		$5K Hold
95
– – ﹤0.01% 2662
2019
Q4 		$5K Buy
95
+29
+44% +$1.92K ﹤0.01% 2662
2019
Q3 		$4K Buy
66
+32
+94% +$2.39K ﹤0.01% 2682
2019
Q2 		$2K Hold
34
– – ﹤0.01% 2831
2019
Q1 		$2K Hold
34
– – ﹤0.01% 2808
2018
Q4 		$1K Buy
+34
New +$1.78K ﹤0.01% 2857
2017
Q3 		– Sell
-398,691
Closed -$19.7M – 2729
2017
Q2 		$19.7M Hold
398,691
– – 0.09% 291
2017
Q1 		$19.7M Buy
398,691
+17,660
+5% +$992K 0.09% 291
2016
Q4 		$23.1M Buy
381,031
+247,538
+185% +$15.1M 0.13% 266
2016
Q3 		$8.86M Buy
+133,493
New +$8.35M 0.05% 376
2015
Q4 		– Sell
-239,113
Closed -$9.45M – 2648
2015
Q3 		$9.45M Buy
+239,113
New +$13.6M 0.07% 345

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
ICOM
Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Glenmede Trust's ANIP Position: Q4 2020 in Review

Glenmede Trust sold out of ANI Pharmaceuticals (ANIP) in Q4 2020, closing a stake of 54 shares — an estimated $1K sold.

Glenmede Trust first reported a position in ANIP in Q3 2015 and held it in 13 quarters. The position peaked at $23.1M in Q4 2016. 117 funds tracked by Wall St. Rank hold ANIP as of Q4 2020.

  • Glenmede Trust reported no remaining ANI Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Glenmede Trust sold 54 ANI Pharmaceuticals shares in Q4 2020, an estimated $1K.
  • Glenmede Trust first reported a position in ANI Pharmaceuticals in Q3 2015 and held it in 13 quarters.
  • Glenmede Trust's ANI Pharmaceuticals position peaked at $23.1M in Q4 2016.
  • 117 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.